{
  "success": true,
  "issues": [
    {
      "issue_type": "possible_hallucination",
      "activity_id": "act_1",
      "activity_name": "Maintenance of clinical response through Week 44",
      "timepoint_id": "pt_3",
      "timepoint_name": "Ustekinumab",
      "confidence": 0.9,
      "details": "Table 7 only has two treatment columns: Placebo and Ustekinumab"
    },
    {
      "issue_type": "possible_hallucination",
      "activity_id": "act_2",
      "activity_name": "Endoscopic healing at Week 44",
      "timepoint_id": "pt_3",
      "timepoint_name": "Ustekinumab",
      "confidence": 0.9,
      "details": "Table 7 only has two treatment columns: Placebo and Ustekinumab"
    },
    {
      "issue_type": "possible_hallucination",
      "activity_id": "act_3",
      "activity_name": "Clinical remission and not receiving concomitant corticosteroids at Week 44",
      "timepoint_id": "pt_3",
      "timepoint_name": "Ustekinumab",
      "confidence": 0.9,
      "details": "Table 7 only has two treatment columns: Placebo and Ustekinumab"
    },
    {
      "issue_type": "possible_hallucination",
      "activity_id": "act_4",
      "activity_name": "Maintenance of clinical remission through Week 44 among the subjects who had achieved clinical remission at maintenance baseline (both global and US definitions)",
      "timepoint_id": "pt_3",
      "timepoint_name": "Ustekinumab",
      "confidence": 0.9,
      "details": "Table 7 only has two treatment columns: Placebo and Ustekinumab"
    }
  ],
  "confirmed_ticks": 8,
  "total_ticks_checked": 12,
  "hallucination_count": 4,
  "missed_count": 0,
  "model_used": "gemini-3-flash-preview",
  "error": null
}